Zynerba Press Releases

11 Jun 21 Zynerba Pharmaceuticals Presents Sleep Data from Study of Zygel™ in Children and Adolescents with Both Developmental and Epileptic Encephalopathies (DEE) and Autism Spectrum Disorder (ASD) at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting

9 Jun 21 Zynerba Pharmaceuticals Announces Adjournment of Annual Meeting

4 Jun 21 Zynerba Pharmaceuticals Announces Acceptance of Poster at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting

3 Jun 21 Zynerba Pharmaceuticals Announces Presentation of Efficacy and Safety Findings in Children and Adolescents with Autism Spectrum Disorder (ASD) and Related Disorders at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

27 May 21 Zynerba Pharmaceuticals Announces Acceptance of Poster at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

26 May 21 Zynerba Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

26 May 21 Notice of Settlement of Derivative Actions

17 May 21 Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the International Society for Pharmacoeconomic and Outcomes Research (ISPOR) Virtual 2021 Conference

12 May 21 Zynerba Pharmaceuticals Reports First Quarter 2021 Financial Results and Operating Highlights

5 May 21 Zynerba Pharmaceuticals Announces Phase 3 RECONNECT Trial Design for Zygel™ in Fragile X Syndrome